The multifunctional characteristics of SDOs, demonstrating both ACE and DPP-IV inhibitory activities [20], offer a distinctive opportunity for the development of dual-action preventive and therapeutic agents, potentially improving homeostasis and leading to effective approaches to treatment for patients with concurrent hypertension and diabetes. Here, FAP is linked to diabetes mellitus.